353 related articles for article (PubMed ID: 8988055)
1. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
3. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
5. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.
Degeorges A; Tatoud R; Fauvel-Lafeve F; Podgorniak MP; Millot G; de Cremoux P; Calvo F
Int J Cancer; 1996 Oct; 68(2):207-14. PubMed ID: 8900430
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
[TBL] [Abstract][Full Text] [Related]
7. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
8. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha.
Hofer DR; Sherwood ER; Bromberg WD; Mendelsohn J; Lee C; Kozlowski JM
Cancer Res; 1991 Jun; 51(11):2780-5. PubMed ID: 2032218
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
10. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
11. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1.
Sakko AJ; Ricciardelli C; Mayne K; Tilley WD; Lebaron RG; Horsfall DJ
Cancer Res; 2001 Feb; 61(3):926-30. PubMed ID: 11221884
[TBL] [Abstract][Full Text] [Related]
12. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
14. Regulation of proliferation and differentiation of prostatic stromal cells by oestradiol through prostatic epithelial cells in a paracrine manner.
Wu Q; Shi J; Chen L; Wang CY; Park I; Lee C; Zhang J
BJU Int; 2008 Feb; 101(4):497-502. PubMed ID: 18190643
[TBL] [Abstract][Full Text] [Related]
15. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
16. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
17. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
18. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
19. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism.
Kong B; Isozaki T; Sasaki S
Gynecol Oncol; 1996 Oct; 63(1):78-84. PubMed ID: 8898173
[TBL] [Abstract][Full Text] [Related]
20. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells.
Sierra A; Price JE; García-Ramirez M; Méndez O; López L; Fabra A
Lab Invest; 1997 Oct; 77(4):357-68. PubMed ID: 9354770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
